Skip to main content

Table 2 Univariate and multivariable associations of MNA and the most frequent investigated health and treatment outcomes in patients with cancer

From: Nutritional status according to the mini nutritional assessment (MNA)® as potential prognostic factor for health and treatment outcomes in patients with cancer – a systematic review

Study

Na

Type of cancer

Mean/ median follow-upb (months)

Association with MNA and

Mortality/ poor survival

Progression-free survival/ Time to progression

Treatment maintenance/

-duration

Complications

Functional status/ -decline

Quality of Life

Treatment toxicity

Postoperative complications

ADL

IADL

Aaldriks 2011

202

Various

9

+ +

 

+

     

Aaldriks 2013a

143

Colorectal

15

any CT: + +

adjuvant CT: – –

palliative: + +

 

+ +

     

Aaldriks 2013b

55

Breast

16

+ +

 

–

     

Aaldriks 2015

44

Various

46

–

 

+ +

     

Aaldriks 2016

494

Various

17

+ +

 

+ +

     

Allaire 2017

144

Bladder

0.2 or

2

    

– –

– –

   

Aparicio 2018

102

Colorectal

20.4

–

–

      

Baier 2016

195

Various

6

     

–

  

Boulahssass 2018

1050

Various

3.3

+ +

       

Decoster 2016

193

Colorectal

2–3

   

Grade 4 HT: – –

Grade 4 NHT: – –

 

–

–

 

Decoster 2018

252

Colorectal

n.r.

 

+ +

–

     

Decoster 2019

2972

Various

3

       

+ +

Dubruille 2015

90

Hematological

12

–

       

Extermann 2012

n.a.c

Various

1

   

HT: – –

NHT: + +

    

Frasca 2018

1264

Various

12

36

60

+ +

+ +

– –

       

Ghosn 2017

100

Various

47.3

–

       

Giannotti 2019

99

Colorectal

12

–

       

Giannousi 2012

122

Lung

70

+ +

       

Gioulbasanis 2011a

173

Lung

24

+ +

+ +

      

Gioulbasanis 2011b

115

Lung

38.2

+ +

       

Gioulbasanis 2012

114

Lung

24.3

+ +

+ +

      

Gioulbasanis 2015

594

Various

27

+ +

       

Goineau 2018

100

Prostate

2

       

–

Gu 2015

300

Renal cell

30.8

+ +

  

– –e

    

Honecker 2018

160

Prostate

n.r.

–

 

–

     

Hoppe 2013

299

Various

n.r.

     

+

  

Kaibori 2016

71

Hepatocellular

n.r.

    

–

   

Kenig 2015

75

Various

1

    

–

   

Kenis 2017

439

Various

n.r.

+ +

    

+ +

–

 

Kenis 2018

Cohort A: 763

Various

Cohort A: 61.4

+ +

       

Cohort B: 402

Cohort B: 45.7

+ +

Kim 2014

98

Various

15.1

  

+ +

     

Kristjansson 2010

182

Colorectal

20

+ +

   

–f

   

Liuu 2020

1092

Various

15.3

+

       

Lycke 2019

944

Various

12

+ +

       

Martucci 2016

136

Various

12

+ +

       

Mazzuca 2019

ProLYOtind: 22

Colorectal

3

   

+

    

Placebo: 25

Michaan 2020

120

Gynaecologic

> 4

+ +

       

Molga 2020

98

Hematological

n.r.

–

 

–

     

Naito 2016

93

Non-Hodgkin Lymphoma

n.r.

–

       

Osborne 2017

178

Prostate

3

   

–

    

Park 2015

70

Lymphomas

21.5

+ +

 

+ +

     

Quinten 2019

Surgery: 741

Various

3

       

+ +

Chemo: 683

–

Retornaz 2020

97

Colorectal

16.7

–

  

–

    

Samuelsson 2019

49

Colorectal

≤0.1

    

–

   

Scholtz 2018

517

Various

1

    

+

   

Schütte 2015

51

Hepatocellular

7.3

+

       

Shin 2012

64

Various

2.1

   

–

    

Shiroyama 2017

30

Lung

n.r.

   

+

    

Soubeyran 2012

348

Various

6

+ +

       

Stauder 2020

147

Hematological

24

+

       

van Deudekom 2019

102

Head & Neck

12

+ +

       

van der Vlies 2019

99

Various

n.r.

  

–

–

    

Vlachostergios 2013

103

Lung

38.2

+ +

–

      

Proportion of studies with significant results in multivariable analyses

   

22/27

(=81%)

3/5

(=40%)

5/8

(=63%)

1/5

(=20%)

0/2

(=0%)

1/3

(=33%)

0/2

(=0%)

2/2

(=100%)

  1. Legend: a: Number of included patients; b: median (range), mean ± SD or pre-defined follow-up time; c: total: 518; d: Highly purified, whey protein group; e: at 30 days; f: 1 month
  2. + +: MNA significantly associated with outcome in multivariable analyses
  3. – –: MNA not significantly associated with outcome in multivariable analyses
  4. +: MNA significantly associated with outcome in univariate regression analyses or by other statistical tests (e.g. chi-square), and no multivariable analyses reported or MNA not included in multivariable model
  5. –: MNA not significantly (p < 0.05) associated with outcome in univariate analyses or by other statistical tests (e.g. chi-square)
  6. HT hematologic toxicity; NHT non-hematologic toxicity; (I)ADL (instrumental) activities of daily living; n.r. not reported
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us